KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Capital Expenditures (2016 - 2026)

Gilead Sciences filings provide 17 years of Capital Expenditures readings, the most recent being $205.0 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 39.46% to $205.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $563.0 million, a 7.65% increase, with the full-year FY2025 number at $563.0 million, up 7.65% from a year prior.
  • Capital Expenditures hit $205.0 million in Q4 2025 for Gilead Sciences, up from $147.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $247.0 million in Q1 2022 to a low of $104.0 million in Q1 2025.
  • Median Capital Expenditures over the past 5 years was $142.0 million (2022), compared with a mean of $148.9 million.
  • Biggest five-year swings in Capital Expenditures: surged 49.7% in 2022 and later tumbled 55.87% in 2023.
  • Gilead Sciences' Capital Expenditures stood at $156.0 million in 2021, then grew by 16.03% to $181.0 million in 2022, then grew by 18.78% to $215.0 million in 2023, then crashed by 31.63% to $147.0 million in 2024, then surged by 39.46% to $205.0 million in 2025.
  • The last three reported values for Capital Expenditures were $205.0 million (Q4 2025), $147.0 million (Q3 2025), and $107.0 million (Q2 2025) per Business Quant data.